THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION
- PMID: 19870634
- PMCID: PMC2133527
- DOI: 10.1084/jem.65.6.787
THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION
Abstract
The response of rhesus monkeys to a subcutaneous inoculation with varying amounts of virus modified by prolonged cultivation in vitro has been studied. The tissue components of the medium consisted of chick embryo tissue containing minimal amounts of nervous tissue. The immunity produced in monkeys, as measured by the antibody titer developed, has no relation to the amount of virus inoculated. Monkeys inoculated subcutaneously with the tissue culture virus are rendered immune to a subsequent injection of a highly virulent yellow fever virus. This resistance is already present 7 days after vaccination. The subcutaneous inoculation of the culture virus into immune persons leads to a substantial increase of the serum antibody titer. The results of vaccinating eight normal persons with culture virus are presented. The reactions were minimal. The highest temperature recorded following vaccination was 37.4 degrees C. The sera taken from the eight vaccinated persons 2 to 4 weeks after inoculation with the tissue culture virus showed the presence of yellow fever antibodies.
Similar articles
-
THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS.J Exp Med. 1937 May 31;65(6):767-86. doi: 10.1084/jem.65.6.767. J Exp Med. 1937. PMID: 19870633 Free PMC article.
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
-
ETIOLOGY OF YELLOW FEVER : X. COMPARATIVE IMMUNOLOGICAL STUDIES ON LEPTOSPIRA ICTEROIDES AND LEPTOSPIRA ICTEROHAEMOORRHAGIAE.J Exp Med. 1920 Jan 31;31(2):135-58. doi: 10.1084/jem.31.2.135. J Exp Med. 1920. PMID: 19868393 Free PMC article.
-
IMMUNITY IN MUMPS : I. EXPERIMENTS WITH MONKEYS (MACACUS MULATTA). THE DEVELOPMENT OF COMPLEMENT-FIXING ANTIBODY FOLLOWING INFECTION AND EXPERIMENTS ON IMMUNIZATION BY MEANS OF INACTIVATED VIRUS AND CONVALESCENT HUMAN SERUM.J Exp Med. 1945 Jan 1;81(1):93-117. doi: 10.1084/jem.81.1.93. J Exp Med. 1945. PMID: 19871448 Free PMC article.
-
VACCINATION AGAINST YELLOW FEVER WITH IMMUNE SERUM AND VIRUS FIXED FOR MICE.J Exp Med. 1932 May 31;55(6):945-69. doi: 10.1084/jem.55.6.945. J Exp Med. 1932. PMID: 19870044 Free PMC article.
Cited by
-
Imidazolium salt's toxic effects in larvae and cells of Aedes aegypti and Aedes albopictus (Diptera: Culicidae).Sci Rep. 2024 Jul 4;14(1):15421. doi: 10.1038/s41598-024-66404-3. Sci Rep. 2024. PMID: 38965297 Free PMC article.
-
Yellow fever in Africa and the Americas: a historical and epidemiological perspective.J Venom Anim Toxins Incl Trop Dis. 2018 Aug 25;24:20. doi: 10.1186/s40409-018-0162-y. eCollection 2018. J Venom Anim Toxins Incl Trop Dis. 2018. PMID: 30158957 Free PMC article. Review.
-
The development of vaccines: how the past led to the future.Nat Rev Microbiol. 2011 Oct 3;9(12):889-93. doi: 10.1038/nrmicro2668. Nat Rev Microbiol. 2011. PMID: 21963800 Review.
-
Catching a Moving Target: Comparative Modeling of Flaviviral NS2B-NS3 Reveals Small Molecule Zika Protease Inhibitors.ACS Med Chem Lett. 2020 Mar 3;11(4):514-520. doi: 10.1021/acsmedchemlett.9b00629. eCollection 2020 Apr 9. ACS Med Chem Lett. 2020. PMID: 32292558 Free PMC article.
-
Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464. doi: 10.1371/journal.pntd.0004464. eCollection 2016 Feb. PLoS Negl Trop Dis. 2016. PMID: 26886513 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources